Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

156.62 -1.93 (-1.22%)
Official Closing Price Updated: 4:10 PM EST, Dec 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,552,278
Open 158.52
Bid (Size) 156.46 (1)
Ask (Size) 156.64 (1)
Prev. Close 158.55
Today's Range 156.17 - 158.66
52wk Range 144.95 - 181.04
Shares Outstanding 2,628,679,824
Dividend Yield 3.04%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities
Johnson & Johnson (NYSE: JNJ) has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chief Executive Officer  
Via Benzinga
Elliott Wave Technical Analysis: Johnson & Johnson
Looking for longs into wave (v). 
Via Talk Markets

Performance

YTD
-12.11%
-12.11%
1 Month
+3.24%
+3.24%
3 Month
-2.53%
-2.53%
6 Month
-0.99%
-0.99%
1 Year
-12.40%
-12.40%

More News

Read More
Bargain Buys: 7 Stocks Lagging the S&P 500 With Big Potential
Via InvestorPlace
Topics Stocks
Exposures US Equities
Johnson & Johnson Settles Multiple Lawsuits Over Talc Cancer Claims, Eyes Prepackaged Bankruptcy
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Is Buffett Turning Bearish? 7 Stocks Warren Completely Dumped in Q3
Via InvestorPlace
Financial Resources Federal Credit Union Goes Live With Scienaptic's AI Platform
Via PRLog
Topics Artificial Intelligence
Exposures Artificial Intelligence
Johnson & Johnson's Strategic Forecast: Targets 5%-6% Operational Sales Growth For FY24
Via Benzinga
Unleashing Growth Potential: Johnson & Johnson Surpasses Expectations with Strong Performance and Increasing Profits
Via Benzinga
Nasdaq 100 Forecast: Stocks Slip For A Second Day With Jobs Data In Focus
Via Talk Markets
Johnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business Review
From Johnson & Johnson
Via Business Wire
The 7 Best Ways to Invest $1,000 in the Stock Market Now
Via InvestorPlace
Top Contenders Emerge in Johnson & Johnson's Race for New CEO, Plans Under Spotlight After Unexpected Departure
Via Benzinga
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
Via MarketBeat
Topics Bonds
Exposures Debt Markets
Supreme Court Decision Looms Over Purdue Pharma's $6B Opioid Settlement And Sackler Family Immunity
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Warren Buffett Just Closed His Position in This Dividend Giant. Should You?
Via The Motley Fool
Barron's Weekend Stock Picks: Uber Joins The S&P 500, Schwab Rebounds And What's Next for Johnson & Johnson?
Via Benzinga
Topics Stocks
Exposures US Equities
Johnson & Johnson Gets Analyst Upgrade Noting Bullish Pharma & MedTech Projections
Via Benzinga
Texas Attorney General Alleges Pfizer Misled Public on COVID-19 Vaccine Efficacy
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Investors Should Not Pay More Than A 15 P/E Ratio When Buying A Stock
Via Talk Markets
Wealth From Wellness: 7 Healthcare Stocks to Inoculate Your Portfolio
Via InvestorPlace
Warren Buffett Reduced This Long-Time Berkshire Hathaway Holding by 67%. Should Investors Follow His Lead?
Via The Motley Fool
Texas Sues Pfizer For "Misrepresenting COVID-19 Vaccine Efficacy" And "Conspiring To Censor Public Discourse"
Via Talk Markets
Topics Lawsuit
Exposures COVID-19 Financial Legal
Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors
From Johnson & Johnson
Via Business Wire
7 Blue-Chip Stocks to Buy for 2024, According to AI
Via InvestorPlace
Income Kings: 7 Blue-Chip Dividend Stocks for Reliable Returns
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.